Companies are continuing to rush out IPOs before the mid-August lull. This past week saw 11 IPOs and one SPAC raise $3.4 billion. Nine went public with market caps over $1 billion, including Chinese e-commerce app Pinduoduo, the...read more
Liquidia Technologies, which is developing engineered formulations of therapies for PAH and pain, raised $50 million by offering 4.55 million shares at $11, within the range of $10 to $12. Insiders had intended to purchase $30 million of the IPO (60% of the deal)...read more
Liquidia Technologies, which is developing engineered formulations of therapies for PAH and pain, announced terms for its IPO on Friday. The Morrisville, NC-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10 to...read more
There are no deals set to price in the upcoming week. Following the most active quarter for IPOs in three years (check out Renaissance Capital's 2Q18 US IPO Review for additional insights), the market...read more
US IPO Weekly Recap: Growth stocks surge in 11 IPO week
Companies are continuing to rush out IPOs before the mid-August lull. This past week saw 11 IPOs and one SPAC raise $3.4 billion. Nine went public with market caps over $1 billion, including Chinese e-commerce app Pinduoduo, the...read more
A liquidity event: Drug developer Liquidia Technologies prices $50 million IPO at $11 midpoint
Liquidia Technologies, which is developing engineered formulations of therapies for PAH and pain, raised $50 million by offering 4.55 million shares at $11, within the range of $10 to $12. Insiders had intended to purchase $30 million of the IPO (60% of the deal)...read more
Hypertension biotech Liquidia Technologies sets terms for $50 million IPO
Liquidia Technologies, which is developing engineered formulations of therapies for PAH and pain, announced terms for its IPO on Friday. The Morrisville, NC-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10 to...read more
US IPO Week Ahead: No IPOs expected, but over 10 deals could launch
There are no deals set to price in the upcoming week. Following the most active quarter for IPOs in three years (check out Renaissance Capital's 2Q18 US IPO Review for additional insights), the market...read more